Risks
4 risks
Risk Intelligence
Oncology facility delays
View Risks →Caplin Point Laboratories Limited — Q3 FY26
Caplin Point reported a steady Q3 FY26 with 10.6% YoY revenue growth and 28.3% PAT margin, driven by strong US sterile injectable approvals and disciplined cost management.
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Caplin Point reported a steady Q3 FY26 with 10.6% YoY revenue growth and 28.3% PAT margin, driven by strong US sterile injectable approvals and disciplined cost management. The US label business has reached nearly $10M in cumulative revenue since inception, with a 75:25 mix of product and milestone income. Management highlighted a consolidation phase over the next 18-24 months as new markets (Mexico, Chile) and oncology injectables ramp up. Key growth drivers include 14-15 injectable lines coming online, a new blow-fill-seal capability, and video SOPs to enhance compliance. Risks include potential delays in oncology facility commercialization and slower-than-expected ramp-up in new Latin American markets.
कैप्लिन पॉइंट ने तीसरी तिमाही में अच्छा प्रदर्शन किया। पिछले साल की तुलना में कमाई 10.6% बढ़ी और मुनाफा 28.3% रहा। इसकी वजह अमेरिका में नए इंजेक्शन उत्पादों की मंजूरी और खर्च पर नियंत्रण है। अमेरिका में अब तक कुल 10 मिलियन डॉलर की कमाई हुई है, जिसमें 75% उत्पाद बिक्री और 25% माइलस्टोन आय है। कंपनी अगले 18-24 महीने स्थिर रहेगी, जब तक मेक्सिको, चिली और कैंसर के इंजेक्शन शुरू नहीं होते। 14-15 नई इंजेक्शन लाइनें, ब्लो-फिल-सील तकनीक और वीडियो SOP से काम बढ़ेगा। जोखिम: कैंसर दवा कारखाने में देरी और लैटिन अमेरिका में धीमी शुरुआत।
Risks4 trackedTranscriptfull text
Research workspace
Focused Modules
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
US label cumulative revenue
$10M
since inception
US label revenue since launch last year, driven by disciplined strategy and supply chain efficiency.
ANDAs approved under Caplin name
65
increasing
Expected soon, with 10 products pending FDA review and 14 ANDAs acquired externally.
CSL EBITDA (Q3)
₹31.09 Cr
not specified
Caplin Steriles Limited EBITDA for quarter ended December 2025.
Capex spent to date
₹385 Cr
of ₹1,000 Cr plan
Out of ₹1,000 Cr capex plan, ₹385 Cr already spent; balance over next 12-18 months.
Fast read
Guidance and risk preview
Expect high double-digit revenue growth in the next years for Caplin Steriles and Caplin USA.
Oncology injectable plant has been delayed from Q1 FY27 to Q3 FY27 due to ecosystem challenges in Tamil Nadu, potentially impacting revenue timelines.
View Risks →